News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty
Photo taken from: Debyani Chakravarty / Twitter
Jul 17, 2023, 09:59

Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty

My OncoKB people: Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC.

Looking fwd to it getting tumor agnostic approval based on Alison Schram work showing 42% ORR in PDAC (& 35% in NSCLC).

 

Source: Debyani Chakravarty / Twitter

FDA OncoDaily Oncology zenocutuzumab
Special Coverage
Opinion
Feb 25, 2025, 06:51
Senator Dan Sullivan in Response to OncoDaily About Pediatric Cancer Funding
Blog
Feb 25, 2025, 05:11
MD Anderson receives nearly $23 million in CPRIT funding for cancer research, faculty recruitment
Insight
Feb 24, 2025, 23:46
Cancer death rates almost 60% higher in UK’s most deprived areas - Cancer Research UK
Blog
Feb 24, 2025, 23:27
Xiuning Le: Honored to serve as a co-chair for IASLC TTLC 2026 and 2027
Blog
Feb 24, 2025, 21:24
ICCD 2025 Event Highlights: Speakers’ Quote Series with Ruth Ladenstein - SIOP Europe
Blog
Feb 24, 2025, 15:25
Bibhudatta Mishra: A paradigm shift in oncology
Blog
Feb 24, 2025, 14:55
Esra Bilir: Women Empowerment at ESGO2025
Blog
Feb 24, 2025, 14:51
Celebrating the Black Volunteer Caucus - ACS CAN
Blog
Feb 24, 2025, 14:45
How can radiotherapy become more environmentally friendly? - ESMO
Blog
Feb 24, 2025, 14:22
Vincent Ling: Where does the money go?
Science
Feb 24, 2025, 14:08
JeeSuk Chang: The 2nd analysis of SABR-5
Stories
Feb 24, 2025, 14:00
Remembering Giovanni Scambia: A Legacy in Gynecological Oncology